Acorda Therapeutics Announces Preclinical Data on GGF2 in Heart Failure ... MarketWatch (press release) GGF2 is currently being evaluated as a treatment for heart failure in a Phase 1 clinical trial. These data were presented at the American Heart Association Scientific Sessions 2011 being held in Orlando, Florida. "These data extend previous preclinical ... |
